{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:48:33Z","timestamp":1778809713752,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To identify factors associated with regional recurrence after lymph node dissection (\n                      <jats:styled-content style=\"fixed-case\">LND<\/jats:styled-content>\n                      ) for squamous cell carcinoma (\n                      <jats:styled-content style=\"fixed-case\">SCC<\/jats:styled-content>\n                      ) to determine which patients might benefit from adjuvant therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Men who underwent\n                      <jats:styled-content style=\"fixed-case\">LND<\/jats:styled-content>\n                      for penile\n                      <jats:styled-content style=\"fixed-case\">SCC<\/jats:styled-content>\n                      from 1977 to 2014 were identified from an institutional database. Kaplan\u2013Meier curves estimated recurrence\u2010free survival (\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      ) calculated from the date of\n                      <jats:styled-content style=\"fixed-case\">LND<\/jats:styled-content>\n                      . Cox regression models evaluated the association between\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      and patient and tumour characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In all, 182 men who underwent\n                      <jats:styled-content style=\"fixed-case\">LND<\/jats:styled-content>\n                      for penile\n                      <jats:styled-content style=\"fixed-case\">SCC<\/jats:styled-content>\n                      were identified. The median patient age was 62 years and the median follow\u2010up was 4.2 years. After\n                      <jats:styled-content style=\"fixed-case\">LND<\/jats:styled-content>\n                      34 men had regional recurrence, of which 24 developed isolated regional recurrences without distant metastasis. The median\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      was 5.7 months, and the 3\u2010year\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      rate was 70%. On univariate analysis, lymphovascular invasion, clinical and pathological nodal stage, pathological inguinal laterality, pelvic nodal involvement, lymph node density \u22655.2%, \u22653 pathologically involved lymph nodes, and extranodal extension (\n                      <jats:styled-content style=\"fixed-case\">ENE<\/jats:styled-content>\n                      ) were associated with worse\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). On multivariate analysis, clinical N3 disease [adjusted hazard ratio (\n                      <jats:styled-content style=\"fixed-case\">AHR<\/jats:styled-content>\n                      )] 3.53, 95% confidence interval (\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ) 1.68\u20137.45;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001), \u22653 pathologically involved lymph nodes (\n                      <jats:styled-content style=\"fixed-case\">AHR<\/jats:styled-content>\n                      3.78, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      2.12\u20136.65;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), and\n                      <jats:styled-content style=\"fixed-case\">ENE<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">AHR<\/jats:styled-content>\n                      3.32, 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      1.93\u20135.76;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) were associated with worse\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      . The 3\u2010year\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      for patients with\n                      <jats:styled-content style=\"fixed-case\">cN<\/jats:styled-content>\n                      0,\n                      <jats:styled-content style=\"fixed-case\">cN<\/jats:styled-content>\n                      1,\n                      <jats:styled-content style=\"fixed-case\">cN<\/jats:styled-content>\n                      2, and\n                      <jats:styled-content style=\"fixed-case\">cN<\/jats:styled-content>\n                      3 disease was 91.7%, 64.5%, 54.7%, and 38.3%, respectively. For men with \u22653 involved nodes, the 3\u2010year\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      was 17% vs 82.4% in men with &lt;3 involved nodes. The 3\u2010year\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      was 29.7% in men with\n                      <jats:styled-content style=\"fixed-case\">ENE<\/jats:styled-content>\n                      and 85.7% in men without ENE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The presence of clinical N3 disease, \u22653 pathologically involved lymph nodes, and\n                      <jats:styled-content style=\"fixed-case\">ENE<\/jats:styled-content>\n                      was associated with worse\n                      <jats:styled-content style=\"fixed-case\">RFS<\/jats:styled-content>\n                      . As regional recurrence portends a dismal prognosis with few salvage options, adjuvant therapies should be developed for men with the aforementioned adverse factors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.13686","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T04:16:42Z","timestamp":1476764202000},"page":"591-597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma"],"prefix":"10.1111","volume":"119","author":[{"given":"Jay P.","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Pettaway","sequence":"additional","affiliation":[{"name":"Department of Urology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence B.","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheroze","family":"Tamboli","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isuru","family":"Jayaratna","sequence":"additional","affiliation":[{"name":"Department of Urology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2001.00379.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.059"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20414"},{"key":"e_1_2_7_5_1","unstructured":"National Comprehensive Cancer Network (NCCN).Penile Cancer 2015. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf. Accessed 17 December 2015."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.06.016"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.140"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.04.008"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0324-6"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e32833efcca"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.07.014"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65169-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12946"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.038"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.029"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)90573-A"},{"key":"e_1_2_7_18_1","first-page":"408","article-title":"Management of regional lymph nodes and their prognostic influence in vulvar cancer","volume":"61","author":"Hacker NF","year":"1983","journal-title":"Obstet Gynecol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/000313481408001004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20279"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.102659"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841868809094366"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.05.008"},{"key":"e_1_2_7_24_1","first-page":"733","article-title":"Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes","volume":"68","author":"Homesley HD","year":"1986","journal-title":"Obstet Gynecol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181b12f99"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.08.013"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12563"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.016"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13686","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:06:26Z","timestamp":1761735986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/bju.13686"],"URL":"https:\/\/doi.org\/10.1111\/bju.13686","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]},"assertion":[{"value":"2016-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}